The lipid composition of highly differentiated human hepatomas, with special reference to fatty acids.
The lipid compositions of homogenates and microsomal fractions derived from surgical samples of highly differentiated human hepatoma, morphologically normal regions outside the tumours and from normal livers were analysed. A few enzyme activities were also assayed. Hepatoma microsomes demonstrated considerably lowered levels of cytochromes P-450 and b5. Hepatoma homogenates exhibited increased levels of cholesterol, normal amounts of dolichyl-P and slightly lowered levels of total phospholipid. The levels of dolichol, dolichol ester and ubiquinone in hepatoma homogenates were prominently decreased. In tumour microsomes the levels of cholesterol and dolichyl phosphate were increased considerably while the levels of phospholipid and dolichol were lowered. The phospholipid composition of tumour homogenates was roughly similar to that of control tissue. In tumour microsomes the relative amounts of phosphatidylserine and phosphatidylinositol were about 30% decreased, whereas the major phospholipids showed minor increases in amount. The rate and pattern of incorporation of [3H]glycerol into individual phospholipids in liver slices from control and hepatoma tissue did not differ to any larger extent. The fatty acid composition of tumour homogenates exhibited minor differences in comparison to the control with the greatest changes in the sphingomyelin fraction. In hepatoma microsomes the fatty acid compositions of the major phospholipids were altered moderately, with evident decreases in the relative amounts of the long-chain polyunsaturated fatty acids. In hepatoma homogenates the fatty acid composition of dolichol esters differed only slightly from the control pattern. These results indicate that the major disturbance in the lipid metabolism of highly differentiated hepatomas is localized to the mevalonate pathway, thus affecting mainly the levels of cholesterol, dolichol and ubiquinone.
Eggens
I
I
Division of Cellular and Neuropathology, Huddinge Hospital, Karolinska Institute, Sweden.
Bäckman
L
L
Jakobsson
A
A
Valtersson
C
C
D006528:Carcinoma, Hepatocellular / Q000032:analysis*; D002784:Cholesterol / Q000032:analysis; D003577:Cytochrome P-450 Enzyme System / Q000032:analysis; D003573:Cytochrome b Group / Q000032:analysis; D015786:Cytochromes b5; D004286:Dolichols / Q000032:analysis; D005227:Fatty Acids / Q000032:analysis*; D006801:Humans; D008055:Lipids / Q000032:analysis*; D008099:Liver / Q000032:analysis; D008113:Liver Neoplasms / Q000032:analysis*; D008862:Microsomes, Liver / Q000032:analysis; D008875:Middle Aged; D010743:Phospholipids / Q000032:analysis; D014451:Ubiquinone / Q000032:analysis
D003573:Cytochrome b Group; D004286:Dolichols; D005227:Fatty Acids; D008055:Lipids; D010743:Phospholipids; D014451:Ubiquinone; D015786:Cytochromes b5; D003577:Cytochrome P-450 Enzyme System; D002784:Cholesterol